Evidence map›Paper›PMID 30152004›Full record

ArticleJournal of the International AIDS Society2018

Perspectives of South African youth in the development of an implant for HIV prevention.

Emily A Krogstad, Millicent Atujuna, Elizabeth T Montgomery, Alexandra Minnis, Sheily Ndwayana, Tsholofelo Malapane, Mary Kate Shapley-Quinn, Kgahlisho Manenzhe, Linda-Gail Bekker, Ariane van der Straten

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Emily A KrogstadDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Millicent AtujunaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Elizabeth T MontgomeryRTI International, Women's Global Health Imperative, Los Angeles, California, USA.
Alexandra MinnisRTI International, Women's Global Health Imperative, San Francisco, California, USA.
Sheily NdwayanaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Tsholofelo MalapaneSetshaba Research Centre, Soshanguve, South Africa.
Mary Kate Shapley-QuinnRTI International, Women's Global Health Imperative, San Francisco, California, USA.
Kgahlisho ManenzheSetshaba Research Centre, Soshanguve, South Africa.
Linda-Gail BekkerDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Ariane van der StratenRTI International, Women's Global Health Imperative, San Francisco, California, USA.
University of Cape Town · ZARTI International · USSetshaba Research Centre · ZADesmond Tutu HIV Foundation · ZASan Francisco AIDS Foundation · USWomen In Technology International · US

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
End-user research to optimize adherence to injectable HIV prevention approachesR01MH105262 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI MONTGOMERY, ELIZABETH TRASK · 2015 to 2017
$1.8M
NIMH NIH HHS P30 MH062246NIMH NIH HHS R01 MH105262PEPFAR
6 · The paper itself

Abstract

introductionImplants are a new dosage form in development for HIV pre-exposure prophylaxis (PrEP) with potential for high adherence given that they are provider-administered and are intended for long-acting protection. Integrating end-user preference into early stage product development may further overcome challenges with future product uptake and adherence. Hence, we sought to optimize the design of a PrEP implant in early-stage development by gathering opinions about implant attributes from potential end-users in South Africa.

methodsWe conducted 14 focus group discussions (FGDs) with young women and men aged 18 to 24 in Cape Town and Soshanguve, South Africa, inviting participants into discussion as co-designers. FGDs were homogenous by gender and previous implant experience. During FGDs, we showed prototype devices and followed a semi-structured guide with questions on history of contraceptive implant use, preferences for physical characteristics of an implant, implant biodegradability, insertion process, participant-driven ideas for implant design, and social adoption considerations. FGDs were facilitated in English, isiXhosa, Tswana, isiZulu, or Tsonga, audio-recorded, transcribed into English, and qualitatively coded and analysed.

resultsIn this qualitative sample of 105 youth (68 women and 37 men), 58 participants were from Soshanguve and 47 from Cape Town, and 23% had previously used contraceptive implants. Participants expressed preferences for several implant design features; specifically, longer duration (≥6 months) was more important to most participants than the size or number of devices implanted. A majority preferred a flexible versus stiff implant to minimize palpability, thereby increasing discreetness and comfort. Nearly all participants favoured a biodegradable implant to avoid removal and thus reduce clinic visits. Concerns about the implant centred on its possible side effects and the "plastic" look of the prototype displayed for demonstration.

conclusionsThis study offers preliminary insights into an implant for HIV prevention that provides long-lasting protection may be well received among young South Africans. Additionally, flexibility, discreetness, and biodegradability may increase acceptability of the implant. Such end-user feedback is being incorporated into current implant designs in the hope of creating an effective long-acting PrEP product that is likely to achieve high uptake and adherence in target populations.

Indexed as

Drug ImplantsAdolescentAnti-HIV AgentsBlack PeopleFemaleFocus GroupsHIV InfectionsHumansMalePre-Exposure ProphylaxisPregnancySouth AfricaYoung AdultAnti-HIV AgentsDrug Implantsadolescentfocus groupsimplantpre-exposure prophylaxisproduct developmentSouth Africa

Identifiers

PMID30152004
PMCPMC6111144
OpenAlexW2889465987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.